We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-7.96%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$1.02B
AUM Growth
-$942M
Cap. Flow
-$762M
Cap. Flow %
-74.8%
Top 10 Hldgs %
36.57%
Holding
87
New
6
Increased
6
Reduced
47
Closed
24

Top Buys

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$15.3M
2
JANX icon
Janux Therapeutics
JANX
+$9.52M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.05M
4
DXCM icon
DexCom
DXCM
+$5.77M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$4.58M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$48.4M
2
ISRG icon
Intuitive Surgical
ISRG
+$43.4M
3
BSX icon
Boston Scientific
BSX
+$39.3M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$29.6M
5
ILMN icon
Illumina
ILMN
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 98.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGNE icon
76
Neurogene
NGNE
$672M
– –
-425,041
Closed -$17.8M
NMRA icon
77
Neumora Therapeutics
NMRA
$306M
– –
-1,800,000
Closed -$21.6M
PRLD icon
78
Prelude Therapeutics
PRLD
$375M
– –
-890,000
Closed -$1.84M
PRME icon
79
Prime Medicine
PRME
$547M
– –
-694,000
Closed -$2.69M
PRVA icon
80
Privia Health
PRVA
$3.04B
– –
-466,800
Closed -$8.5M
SNY icon
81
Sanofi
SNY
$107B
– –
-100,000
Closed -$5.76M
TERN
82
DELISTED
Terns Pharmaceuticals
TERN
– –
-2,133,872
Closed -$17.8M
TIL icon
83
Instil Bio
TIL
$49M
– –
-29,100
Closed -$1.96M
ZTS icon
84
Zoetis
ZTS
$32.7B
– –
-71,000
Closed -$13.9M
ANRO icon
85
Alto Neuroscience
ANRO
$1.04B
– –
-240,000
Closed -$2.75M
SYRS
86
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-1,063,000
Closed -$2.29M
CMAX
87
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
– –
-21,200
Closed -$36K
1 2 3
4

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2024 Portfolio in Review

As of Q4 2024, Avidity Partners Management held 87 positions worth $1.02B, down 48% from $1.96B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Avidity Partners Management withdrew a net $762M in Q4 2024, closing 24 positions and reducing 47 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $22.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Avidity Partners Management opened a new position in Regeneron Pharmaceuticals worth $5.98M.

  • Avidity Partners Management's largest Q4 2024 buy was Regeneron Pharmaceuticals: 8,400 shares worth $5.98M.
  • Avidity Partners Management added most to Transmedics in Q4 2024, an estimated $15.3M increase.
  • Avidity Partners Management's biggest Q4 2024 reduction was Natera, cutting an estimated $48.4M.
  • Avidity Partners Management fully exited BioMarin Pharmaceuticals in Q4 2024, selling an estimated $22.5M.
  • Avidity Partners Management's ten largest holdings make up 37% of its $1.02B portfolio in Q4 2024.
  • Avidity Partners Management opened 6 new positions and closed 24 in Q4 2024.
  • Avidity Partners Management's portfolio value fell 48% quarter-over-quarter to $1.02B.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.